English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background Brd4 (bromodomain-containing protein 4) is an important epigenetic reader that plays a crucial role in cellular proliferation and cell cycle progression. Several recent studies have identified Brd4 as a critical therapeutic target in a number of different cancers. Brd4 is also an important target of several oncogenic viruses and the translocation t (15;19) that accounts for a highly aggressive carcinoma. The t(15;19) translocation results in the novel in-frame fusion of the Brd4 N-terminal component with almost the entire sequence of Nut (Nuclear protein in testis) molecule, leading to the formation of a novel fusion oncogene, Brd4-Nut. The mechanism by which the Brd4-Nut fusion product contributes to oncogenesis remains to be clearly defined.

Abrogation of Brd4 cellular function contributes to the oncogenic mechanisms of translocation t(15;19)-associated carcinoma